{"pub": "cnbc", "url": "https://cnbc.com/2018/07/23/pro-talks-top-biotech-investor-and-icahn-protege-talks-biogen-trump-.html", "downloaded_at": "2019-10-29 02:13:24.494521+00:00", "title": "PRO Talks: Top biotech investor and Icahn protege talks Biogen, Trump and best picks", "language": "en", "text": "Sarissa Capital Management chief investment officer Alex Denner spoke with CNBC Pro for an exclusive interview from the Delivering Alpha Conference in New York, and detailed his case for investing in Biogen.\n\nLike other shareholder activists, Denner's approach focuses on improving the strategies of companies to unlock otherwise trapped equity value. Having previously served as a managing director at Icahn Capital \u2014 an entity through which famed activist Carl Icahn conducts his investment activities \u2014 Denner's current investments include a number of large biotechnology and pharmaceutical companies.\n\nSarissa oversees $535 million in assets under management according to its latest Form ADV filing.\n\nThe investors also talked:", "description": "", "authors": ["Thomas Franck"], "top_image": "https://image.cnbcfm.com/api/v1/image/100984225-169200444.jpg?v=1571755528", "published_at": "2018-07-23"}